Abstract:AF9 (MLLT3) and its paralog ENL(MLLT1) are members of the YEATS family of proteins with important role in transcriptional and epigenetic regulatory complexes. These proteins are two common MLL fusion partners in MLL‐rearranged leukemias. The oncofusion proteins MLL‐AF9/ENL recruit multiple binding partners, including the histone methyltransferase DOT1L, leading to aberrant transcriptional activation and enhancing the expression of a characteristic set of genes that drive leukemogenesis. The interaction between AF9 and DOT1L is mediated by an intrinsically disordered C‐terminal ANC1 homology domain (AHD) in AF9, which undergoes folding upon binding of DOT1L and other partner proteins. We have recently reported peptidomimetics that disrupt the recruitment of DOT1L by AF9 and ENL, providing a proof‐of‐concept for targeting AHD and assessing its druggability. Intrinsically disordered proteins, such as AF9 AHD, are difficult to study and characterize experimentally on a structural level. In this study, we present a successful protein engineering strategy to facilitate structural investigation of the intrinsically disordered AF9 AHD domain in complex with peptidomimetic inhibitors by using maltose binding protein (MBP) as a crystallization chaperone connected with linkers of varying flexibility and length. The strategic incorporation of disulfide bonds provided diffraction‐quality crystals of the two disulfide‐bridged MBP–AF9 AHD fusion proteins in complex with the peptidomimetics. These successfully determined first series of 2.1–2.6 Å crystal complex structures provide high‐resolution insights into the interactions between AHD and its inhibitors, shedding light on the role of AHD in recruiting various binding partner proteins. We show that the overall complex structures closely resemble the reported NMR structure of AF9 AHD/DOT1L with notable difference in the conformation of the β‐hairpin region, stabilized through conserved hydrogen bonds network. These first series of AF9 AHD/peptidomimetics complex structures are providing insights of the protein–inhibitor interactions and will facilitate further development of novel inhibitors targeting the AF9/ENL AHD domain.

Structural insights into rapamycin‐induced oligomerization of a FRB–FKBP fusion protein

Rational design and implementation of a chemically inducible heterotrimerization system

Structural Characterization of the RyR1-FKBP12 Interaction.

An evaluation tool for FKBP12-dependent and -independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR

A Curvilinear-Path Umbrella Sampling Approach to Characterizing the Interactions Between Rapamycin and Three FKBP12 Variants

Blue Light Activated Rapamycin for Optical Control of Protein Dimerization in Cells and Zebrafish Embryos

Structural Insights into Ryanodine Receptor-FKBP12 Interactions in Wild-Type and Mutated States

Cell-free expression and SMA copolymer encapsulation of a functional receptor tyrosine kinase disease variant, FGFR3-TACC3

Quantitative Analysis of Ligand Induced Heterodimerization of Two Distinct Receptors

Discovery of fully synthetic FKBP12-mTOR molecular glues

Spontaneous Dimerization and Distinct Packing Modes of Transmembrane Domains in Receptor Tyrosine Kinases

Crystal structures of ryanodine receptor SPRY1 and tandem-repeat domains reveal a critical FKBP12 binding determinant

Structural Refinement of Proteins by Restrained Molecular Dynamics Simulations with Non-Interacting Molecular Fragments

Structural studies of intrinsically disordered MLL‐fusion protein AF9 in complex with peptidomimetic inhibitors

Simulations of PKA RIα Homodimer Reveal cAMP-coupled Conformational Dynamics of Each Protomer and the Dimer Interface with Functional Implications

Structure of prolylrapamycin: confirmation through a revised and detailed NMR assignment study

FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells

Design of High-affinity Stapled Peptides to Target the Repressor Activator Protein 1 (RAP1)/Telomeric Repeat-binding Factor 2 (TRF2) Protein-Protein Interaction in the Shelterin Complex.

Discovery of pentapeptide-inhibitor hits targeting FKBP51 by combining computational modeling and X-ray crystallography

Ribosomal crystallography: peptide bond formation and its inhibition

Analysis of homodimer formation in 12-oxophytodienoate reductase 3 in solutio and crystallo challenges the physiological role of the dimer